ReviewCytokine & growth factor reviews2014
Interferons: Success in anti-viral immunotherapy.
Review in Cytokine & growth factor reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 255 citations in OpenAlex.
- The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.Journal of Alzheimer's disease : JAD · 2023Pooled it
- The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.Life sciences · 2020Pooled it
- Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.International immunopharmacology · 2020Trial
- A hepcidin homolog fromVirulence · 2026Article
- Respiratory mucosal vaccines for emerging viruses: promise and challenges.Journal of virology · 2026Review
- The adult nasal mucosa is defined by distinct immune profiles that modulate in-vitro SARS-CoV-2 infection.Respiratory research · 2026Article
- CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2.Molecular medicine (Cambridge, Mass.) · 2026Article
- Protease Inhibitors and Innate Immune Agonists as Antiviral Strategies Against Dengue and Zika Viruses.Pathogens (Basel, Switzerland) · 2026Review
- The adult nasal mucosa is defined by distinct immune profiles that modulate in-vitro SARS-CoV-2 infection.Research square · 2026Article
- Porcine interferon-alpha but not interferon-lambda inhibits replication of genotypically diverse PRRSV isolatesFrontiers in veterinary science · 2026Article
- Therapeutic and preventive treatment on outcomes of hepatitis B virus induced chronic liver disease with a cost-effectiveness analysis.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Review
- An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus.CPT: pharmacometrics & systems pharmacology · 2025Article
- Optimized production and antiviral activity evaluation of recombinant chicken interferon-alpha using an improved Baculovirus expression system.Poultry science · 2025Article
- Potential mechanisms implied in tick infection by arboviruses and their transmission to vertebrate hosts.Integrative zoology · 2025Review
- Expression and function of interferon lambda receptor 1 variants.FEBS letters · 2025Review
- Betrixaban is a broad anti-virus inhibitor by activating innate immunity.Frontiers in cellular and infection microbiology · 2025Article
- IFN-γ derived from activated human CD4Scientific reports · 2024Article
- Mycophenolate mofetil for the long-term treatment of HTLV-1 associated myelopathy: A case report.Journal of neuroimmunology · 2024Article
- Hepatitis B virus evades the immune system by suppressing the NF-κB signaling pathway with DENND2A.Microbiology spectrum · 2024Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the first lines of host defense against invading pathogens. These proteins are classified into three groups, Type I, II and III IFNs, based on the structure of their receptors on the cell surface. Due to their ability to modulate immune responses, they have become attractive therapeutic options to control chronic virus infections. In combination with other drugs, Type I IFNs are considered as "standard of care" in suppressing Hepatitis C (HCV) and Hepatitis B (HBV) infections, while Type III IFN has generated encouraging results as a treatment for HCV infection in phase III clinical trials. However, though effective, using IFNs as a treatment is not without the need for caution. IFNs are such powerful cytokines that affect a wide array of cell types; as a result, patients usually experience unpleasant symptoms, with a percentage of patients suffering system wide effects. Thus, constant monitoring is required for patients treated with IFN in order to reach the treatment goals of suppressing virus infection and maintaining quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.